Skip to main content
Top
Published in: BMC Pulmonary Medicine 1/2023

Open Access 01-12-2023 | Idiopathic Pulmonary Fibrosis | Research

Characteristics of idiopathic pulmonary fibrosis -associated cough. a case-control study

Authors: Eeva Saari, Minna Mononen, Hannele Hasala, Anne Lätti, Johanna Kaulamo, Hanna Nurmi, Riitta Kaarteenaho, Minna Purokivi, Heikki O Koskela

Published in: BMC Pulmonary Medicine | Issue 1/2023

Login to get access

Abstract

Background

Most patients with idiopathic pulmonary fibrosis (IPF) complain of cough. IPF-associated cough is widely characterized as dry or non-productive. The aim of this study was to compare chronic cough in early stage IPF patients to cough in subjects with chronic cough from a community-based sample and, especially, to investigate whether cough in IPF is less productive than chronic cough in a community-based sample.

Methods

The IPF cough population consisted of 46 biopsy-confirmed patients who complained of chronic cough. Control population consisted of subjects with chronic cough, gathered by a community-based email survey sent to public service employees and the Finnish Pensioners’ Federation. A case-control setting was applied by having four age, gender, and smoking-status matched subjects from the community sample for each IPF cough patient. A cough specific quality of life questionnaire (Leicester Cough Questionnaire (LCQ)) was filled in by all subjects. The LCQ questionnaire contains 19 questions, each question is scored from 1 to 7 and total score from 3 to 21 with a smaller value indicating more severe impairment.

Results

The sputum production frequency, as assessed by LCQ question 2, was 5.0 (3.0-6.0) in the IPF chronic cough population and 5.0 (3.0–6.0) in the community-based chronic cough population (median and interquartile range p= 0.72). The LCQ total score was 14.8 (11.5-18.1) in the IPF chronic cough population and 15.4 (13.0–17.5) in the community-based chronic cough population (p=0.76). The domain impact scores were physical, 4.9 (3.9–6.1) vs. 5.1 (4.5–5.6) (p=0.80); psychological, 4.6 (3.7–5.9) vs. 4.7 (3.9–5.7) (p=0.90); and social, 5.5 (3.7–6.5) vs. 5.5 (4.5–6.3) (p=0.84), respectively. Furthermore, cough response to paint or fumes, cough disturbing sleep, and cough frequency per day did not differ between the groups.

Conclusion

Cough in early stage IPF patients was not distinguishable from chronic cough in the community-based population by LCQ. Especially, there was no difference in the self-reported frequency of cough-associated sputum production.
Literature
1.
go back to reference Finley CR, Chan DS, Garrison S, Korownyk C, Kolber MR, Campbell S. What are the most common conditions in primary care? Systematic review. Can Fam Physician. 2018;64(11):832–40.PubMedPubMedCentral Finley CR, Chan DS, Garrison S, Korownyk C, Kolber MR, Campbell S. What are the most common conditions in primary care? Systematic review. Can Fam Physician. 2018;64(11):832–40.PubMedPubMedCentral
2.
go back to reference Lätti AM, Pekkanen J, Koskela HO. Defining the risk factors for acute, subacute and chronic cough: a cross-sectional study in a Finnish adult employee population. BMJ Open. 2018;8(7):e022950.CrossRefPubMedPubMedCentral Lätti AM, Pekkanen J, Koskela HO. Defining the risk factors for acute, subacute and chronic cough: a cross-sectional study in a Finnish adult employee population. BMJ Open. 2018;8(7):e022950.CrossRefPubMedPubMedCentral
3.
go back to reference Raghu G, Collard HR, Egan JJ, Martinez FJ, Behr J, Brown KK. An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med. 2011;183(6):788–824.CrossRefPubMedPubMedCentral Raghu G, Collard HR, Egan JJ, Martinez FJ, Behr J, Brown KK. An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med. 2011;183(6):788–824.CrossRefPubMedPubMedCentral
4.
go back to reference Behr J, Kreuter M, Hoeper MM, Wirtz H, Klotsche J, Koschel D. Management of patients with idiopathic pulmonary fibrosis in clinical practice: the INSIGHTS-IPF registry. Eur Respir J. 2015;46(1):186–96.CrossRefPubMedPubMedCentral Behr J, Kreuter M, Hoeper MM, Wirtz H, Klotsche J, Koschel D. Management of patients with idiopathic pulmonary fibrosis in clinical practice: the INSIGHTS-IPF registry. Eur Respir J. 2015;46(1):186–96.CrossRefPubMedPubMedCentral
5.
go back to reference Ryerson CJ, Abbritti M, Ley B, Elicker BM, Jones KD, Collard HR. Cough predicts prognosis in idiopathic pulmonary fibrosis. Respirology. 2011;16(6):969–75.CrossRefPubMed Ryerson CJ, Abbritti M, Ley B, Elicker BM, Jones KD, Collard HR. Cough predicts prognosis in idiopathic pulmonary fibrosis. Respirology. 2011;16(6):969–75.CrossRefPubMed
6.
go back to reference Hope-Gill BD, Hilldrup S, Davies C, Newton RP, Harrison NK. A study of the cough reflex in idiopathic pulmonary fibrosis. AmJRespirCritCare Med. 2003;168(8):995–1002. Hope-Gill BD, Hilldrup S, Davies C, Newton RP, Harrison NK. A study of the cough reflex in idiopathic pulmonary fibrosis. AmJRespirCritCare Med. 2003;168(8):995–1002.
7.
go back to reference Rajala K, Lehto JT, Sutinen E, Kautiainen H, Myllärniemi M, Saarto T. mMRC dyspnoea scale indicates impaired quality of life and increased pain in patients with idiopathic pulmonary fibrosis. ERJ Open Res. 2017;3(4):00084–2017.CrossRefPubMedPubMedCentral Rajala K, Lehto JT, Sutinen E, Kautiainen H, Myllärniemi M, Saarto T. mMRC dyspnoea scale indicates impaired quality of life and increased pain in patients with idiopathic pulmonary fibrosis. ERJ Open Res. 2017;3(4):00084–2017.CrossRefPubMedPubMedCentral
8.
go back to reference Lee J, White E, Freiheit E, Scholand MB, Strek ME, Podolanczuk AJ. Cough-Specific Quality of Life Predicts Disease Progression Among Patients With Interstitial Lung Disease: Data From the Pulmonary Fibrosis Foundation Patient Registry. Chest. 2022;162(3):603–13.CrossRefPubMed Lee J, White E, Freiheit E, Scholand MB, Strek ME, Podolanczuk AJ. Cough-Specific Quality of Life Predicts Disease Progression Among Patients With Interstitial Lung Disease: Data From the Pulmonary Fibrosis Foundation Patient Registry. Chest. 2022;162(3):603–13.CrossRefPubMed
9.
go back to reference Wakwaya Y, Ramdurai D, Swigris JJ. Managing Cough in Idiopathic Pulmonary Fibrosis. Chest. 2021;160(5):1774–82.CrossRefPubMed Wakwaya Y, Ramdurai D, Swigris JJ. Managing Cough in Idiopathic Pulmonary Fibrosis. Chest. 2021;160(5):1774–82.CrossRefPubMed
10.
go back to reference Guenther A, Krauss E, Tello S, Wagner J, Paul B, Kuhn S, et al. The European IPF registry (eurIPFreg): baseline characteristics and survival of patients with idiopathic pulmonary fibrosis. Respir Res. 2018;19(1):141.CrossRefPubMedPubMedCentral Guenther A, Krauss E, Tello S, Wagner J, Paul B, Kuhn S, et al. The European IPF registry (eurIPFreg): baseline characteristics and survival of patients with idiopathic pulmonary fibrosis. Respir Res. 2018;19(1):141.CrossRefPubMedPubMedCentral
11.
go back to reference Bargagli E, Di Masi M, Perruzza M, Vietri L, Bergantini L, Torricelli E. The pathogenetic mechanisms of cough in idiopathic pulmonary fibrosis. Intern Emerg Med. 2018;14(1):39–43.CrossRefPubMed Bargagli E, Di Masi M, Perruzza M, Vietri L, Bergantini L, Torricelli E. The pathogenetic mechanisms of cough in idiopathic pulmonary fibrosis. Intern Emerg Med. 2018;14(1):39–43.CrossRefPubMed
12.
go back to reference Emilsson ÖI. The burden and impact of chronic cough in severe disease. Curr Opin Support Palliat Care. 2022;16(4):183–7.CrossRefPubMed Emilsson ÖI. The burden and impact of chronic cough in severe disease. Curr Opin Support Palliat Care. 2022;16(4):183–7.CrossRefPubMed
13.
go back to reference Irwin RS, French CL, Chang AB, Altman KW, CHEST Expert Cough Panel*. Classification of Cough as a Symptom in Adults and Management Algorithms: CHEST Guideline and Expert Panel Report. Chest. 2018;153(1):196–209.CrossRefPubMed Irwin RS, French CL, Chang AB, Altman KW, CHEST Expert Cough Panel*. Classification of Cough as a Symptom in Adults and Management Algorithms: CHEST Guideline and Expert Panel Report. Chest. 2018;153(1):196–209.CrossRefPubMed
14.
go back to reference Mononen M, Saari E, Hasala H, Kettunen HP, Suoranta S, Nurmi H, et al. Risk factors of clinically significant complications in transbronchial lung cryobiopsy: A prospective multi-center study. Respir Med. 2022;200:106922. Mononen M, Saari E, Hasala H, Kettunen HP, Suoranta S, Nurmi H, et al. Risk factors of clinically significant complications in transbronchial lung cryobiopsy: A prospective multi-center study. Respir Med. 2022;200:106922.
15.
go back to reference Raghu G, Rochwerg B, Zhang Y, Garcia CA, Azuma A, Behr J. An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline: Treatment of Idiopathic Pulmonary Fibrosis. An Update of the 2011 Clinical Practice Guideline. Am J Respir Crit Care Med. 2015;192(2):3.CrossRef Raghu G, Rochwerg B, Zhang Y, Garcia CA, Azuma A, Behr J. An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline: Treatment of Idiopathic Pulmonary Fibrosis. An Update of the 2011 Clinical Practice Guideline. Am J Respir Crit Care Med. 2015;192(2):3.CrossRef
16.
go back to reference Raghu G, Remy-Jardin M, Myers JL, Richeldi L, Ryerson CJ, Lederer DJ. Diagnosis of Idiopathic Pulmonary Fibrosis. An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline. Am J Respir Crit Care Med. 2018;198(5):e44-68.CrossRefPubMed Raghu G, Remy-Jardin M, Myers JL, Richeldi L, Ryerson CJ, Lederer DJ. Diagnosis of Idiopathic Pulmonary Fibrosis. An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline. Am J Respir Crit Care Med. 2018;198(5):e44-68.CrossRefPubMed
17.
go back to reference Ley B, Ryerson CJ, Vittinghoff E, Ryu JH, Tomassetti S, Lee JS. A multidimensional index and staging system for idiopathic pulmonary fibrosis. Ann Intern Med. 2012;156(10):684–91.CrossRefPubMed Ley B, Ryerson CJ, Vittinghoff E, Ryu JH, Tomassetti S, Lee JS. A multidimensional index and staging system for idiopathic pulmonary fibrosis. Ann Intern Med. 2012;156(10):684–91.CrossRefPubMed
19.
go back to reference Birring SS, Prudon B, Carr AJ, Singh SJ, Morgan MDL, Pavord ID. Development of a symptom specific health status measure for patients with chronic cough: Leicester Cough Questionnaire (LCQ). Thorax. 2003;58(4):339–43.CrossRefPubMedPubMedCentral Birring SS, Prudon B, Carr AJ, Singh SJ, Morgan MDL, Pavord ID. Development of a symptom specific health status measure for patients with chronic cough: Leicester Cough Questionnaire (LCQ). Thorax. 2003;58(4):339–43.CrossRefPubMedPubMedCentral
21.
go back to reference Scholand MB, Wolff R, Crossno PF, Sundar K, Winegar M, Whipple S, et al. Severity of cough in idiopathic pulmonary fibrosis is associated with MUC5 B genotype. Cough. 2014;10:3.CrossRefPubMedPubMedCentral Scholand MB, Wolff R, Crossno PF, Sundar K, Winegar M, Whipple S, et al. Severity of cough in idiopathic pulmonary fibrosis is associated with MUC5 B genotype. Cough. 2014;10:3.CrossRefPubMedPubMedCentral
22.
go back to reference Sato R, Handa T, Matsumoto H, Kubo T, Hirai T. Clinical significance of self-reported cough intensity and frequency in patients with interstitial lung disease: a cross-sectional study. BMC PulmMed. 2019;19(1):247–6. Sato R, Handa T, Matsumoto H, Kubo T, Hirai T. Clinical significance of self-reported cough intensity and frequency in patients with interstitial lung disease: a cross-sectional study. BMC PulmMed. 2019;19(1):247–6.
23.
go back to reference Pullerits T, Ternesten-Hasséus E, Johansson EL, Millqvist E. Capsaicin cough threshold test in diagnostics. Respir Med. 2014;108(9):1371–6.CrossRefPubMed Pullerits T, Ternesten-Hasséus E, Johansson EL, Millqvist E. Capsaicin cough threshold test in diagnostics. Respir Med. 2014;108(9):1371–6.CrossRefPubMed
24.
go back to reference Millqvist E, Ternesten-Hasséus E, Ståhl A, Bende M. Changes in levels of nerve growth factor in nasal secretions after capsaicin inhalation in patients with airway symptoms from scents and chemicals. Environ Health Perspect. 2005;113(7):849–52.CrossRefPubMedPubMedCentral Millqvist E, Ternesten-Hasséus E, Ståhl A, Bende M. Changes in levels of nerve growth factor in nasal secretions after capsaicin inhalation in patients with airway symptoms from scents and chemicals. Environ Health Perspect. 2005;113(7):849–52.CrossRefPubMedPubMedCentral
25.
go back to reference Ternesten-Hasséus E, Johansson K, Löwhagen O, Millqvist E. Inhalation method determines outcome of capsaicin inhalation in patients with chronic cough due to sensory hyperreactivity. Pulm Pharmacol Ther. 2006;19(3):172–8.CrossRefPubMed Ternesten-Hasséus E, Johansson K, Löwhagen O, Millqvist E. Inhalation method determines outcome of capsaicin inhalation in patients with chronic cough due to sensory hyperreactivity. Pulm Pharmacol Ther. 2006;19(3):172–8.CrossRefPubMed
26.
go back to reference Schertel A, Funke-Chambour M, Geiser T, Brill AK. Novel insights in cough and breathing patterns of patients with idiopathic pulmonary fibrosis performing repeated 24-hour-respiratory polygraphies. Respir Res. 2017;18(1):190-y.CrossRefPubMedPubMedCentral Schertel A, Funke-Chambour M, Geiser T, Brill AK. Novel insights in cough and breathing patterns of patients with idiopathic pulmonary fibrosis performing repeated 24-hour-respiratory polygraphies. Respir Res. 2017;18(1):190-y.CrossRefPubMedPubMedCentral
27.
go back to reference Zaman T, Moua T, Vittinghoff E, Ryu JH, Collard HR, Lee JS. Differences in Clinical Characteristics and Outcomes Between Men and Women With Idiopathic Pulmonary Fibrosis: A Multicenter Retrospective Cohort Study. Chest. 2020;158(1):245–51.CrossRefPubMedPubMedCentral Zaman T, Moua T, Vittinghoff E, Ryu JH, Collard HR, Lee JS. Differences in Clinical Characteristics and Outcomes Between Men and Women With Idiopathic Pulmonary Fibrosis: A Multicenter Retrospective Cohort Study. Chest. 2020;158(1):245–51.CrossRefPubMedPubMedCentral
28.
go back to reference van Manen MJG, Birring SS, Vancheri C, Cottin V, Renzoni EA, Russell AM. Cough in idiopathic pulmonary fibrosis. Eur Respir Rev. 2016;25(141):278–86.CrossRefPubMedPubMedCentral van Manen MJG, Birring SS, Vancheri C, Cottin V, Renzoni EA, Russell AM. Cough in idiopathic pulmonary fibrosis. Eur Respir Rev. 2016;25(141):278–86.CrossRefPubMedPubMedCentral
29.
go back to reference Mermigkis C, Stagaki E, Tryfon S, Schiza S, Amfilochiou A, Polychronopoulos V. How common is sleep-disordered breathing in patients with idiopathic pulmonary fibrosis? Sleep Breath. 2010;14(4):387–90.CrossRefPubMed Mermigkis C, Stagaki E, Tryfon S, Schiza S, Amfilochiou A, Polychronopoulos V. How common is sleep-disordered breathing in patients with idiopathic pulmonary fibrosis? Sleep Breath. 2010;14(4):387–90.CrossRefPubMed
30.
go back to reference Kilduff CE, Counter MJ, Thomas GA, Harrison NK, Hope-Gill BD. Effect of acid suppression therapy on gastroesophageal reflux and cough in idiopathic pulmonary fibrosis: an intervention study. Cough. 2014;10:4.CrossRefPubMedPubMedCentral Kilduff CE, Counter MJ, Thomas GA, Harrison NK, Hope-Gill BD. Effect of acid suppression therapy on gastroesophageal reflux and cough in idiopathic pulmonary fibrosis: an intervention study. Cough. 2014;10:4.CrossRefPubMedPubMedCentral
Metadata
Title
Characteristics of idiopathic pulmonary fibrosis -associated cough. a case-control study
Authors
Eeva Saari
Minna Mononen
Hannele Hasala
Anne Lätti
Johanna Kaulamo
Hanna Nurmi
Riitta Kaarteenaho
Minna Purokivi
Heikki O Koskela
Publication date
01-12-2023
Publisher
BioMed Central
Published in
BMC Pulmonary Medicine / Issue 1/2023
Electronic ISSN: 1471-2466
DOI
https://doi.org/10.1186/s12890-023-02476-7

Other articles of this Issue 1/2023

BMC Pulmonary Medicine 1/2023 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.